281 related articles for article (PubMed ID: 17705569)
1. Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study.
Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
Clin Drug Investig; 2007; 27(9):605-11. PubMed ID: 17705569
[TBL] [Abstract][Full Text] [Related]
2. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects.
Darwish M; Kirby M; Jiang JG; Tracewell W; Robertson P
Clin Drug Investig; 2008; 28(1):1-7. PubMed ID: 18081355
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.
Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
Clin Ther; 2006 May; 28(5):707-14. PubMed ID: 16861092
[TBL] [Abstract][Full Text] [Related]
5. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics.
Darwish M; Kirby M; Robertson P; Hellriegel E; Jiang JG
Clin Pharmacokinet; 2006; 45(8):843-50. PubMed ID: 16884321
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review.
Darwish M; Xie F
Pain Pract; 2012 Apr; 12(4):307-14. PubMed ID: 21831253
[TBL] [Abstract][Full Text] [Related]
7. Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300 microg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study.
Darwish M; Kirby M; Robertson P; Tracewell W; Xie F
Clin Drug Investig; 2010; 30(6):365-73. PubMed ID: 20441245
[TBL] [Abstract][Full Text] [Related]
8. Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer.
Blick SK; Wagstaff AJ
Drugs; 2006; 66(18):2387-93; discussion 2394-5. PubMed ID: 17181383
[TBL] [Abstract][Full Text] [Related]
9. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
10. Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet.
Darwish M; Kirby M; Jiang JG
Expert Opin Pharmacother; 2007 Sep; 8(13):2011-6. PubMed ID: 17714055
[TBL] [Abstract][Full Text] [Related]
11. Fentanyl buccal tablet.
Messina J; Darwish M; Fine PG
Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Pharmacokinet; 2005; 44(12):1279-86. PubMed ID: 16372825
[TBL] [Abstract][Full Text] [Related]
13. Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study.
Finn AL; Vasisht N; Stark JG; Gever LN; Tagarro I
Clin Drug Investig; 2012 Jan; 32(1):63-71. PubMed ID: 22128878
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
Lennernäs B; Hedner T; Holmberg M; Bredenberg S; Nyström C; Lennernäs H
Br J Clin Pharmacol; 2005 Feb; 59(2):249-53. PubMed ID: 15676050
[TBL] [Abstract][Full Text] [Related]
15. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer.
Portenoy RK; Taylor D; Messina J; Tremmel L
Clin J Pain; 2006; 22(9):805-11. PubMed ID: 17057563
[TBL] [Abstract][Full Text] [Related]
17. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study.
Weinstein SM; Messina J; Xie F
Cancer; 2009 Jun; 115(11):2571-9. PubMed ID: 19373888
[TBL] [Abstract][Full Text] [Related]
18. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
Portenoy RK; Messina J; Xie F; Peppin J
Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
[TBL] [Abstract][Full Text] [Related]
19. Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers.
Darwish M; Tempero K; Jiang JG; Simonson PG
Arch Drug Inf; 2008 Sep; 1(2):50-55. PubMed ID: 19915714
[TBL] [Abstract][Full Text] [Related]
20. Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study.
Finn AL; Vasisht N; Stark JG; Gever LN; Tagarro I
Clin Drug Investig; 2012 Jan; 32(1):63-71. PubMed ID: 27933600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]